Pfizer announced the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. This first Phase 3 trial will enroll an estimated 3,880 adults and is designed to compare immune responses after 20vPnC administration to responses in control subjects greater than or equal to60 years old receiving 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine; evaluate the immunogenicity of 20vPnC in adults 18-59 years of age; and describe the 20vPnC safety profile in adults greater than or equal to18 years old. More on the study can be found on http://www.clinicaltrials.gov under the identifier NCT03760146.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.